* Nyxoah SA NYXH.BR reported a quarterly adjusted loss
of 38
cents per share for the quarter ended in December, higher than
the same quarter last year, when the company reported EPS of -51
cents. The mean expectation of six analysts for the quarter was
for a loss of 38 cents per share. Wall Street expected
results to range from -49 cents to -26 cents per share.
* Revenue rose 39.6% to €1.82 million from a year ago;
analysts
expected €1.71 million.
* Nyxoah SA's reported EPS for the quarter was a loss of 38
cents.
* The company reported a quarterly loss of €10.84 million.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Nyxoah SA is
€12.65
This summary was machine generated from LSEG data March 5 at
11:30 p.m. UTC. All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.38 -0.38 Met
Sep. 30 2023 -0.42 -0.27 Beat
Jun. 30 2023 -0.41 -0.45 Missed
Mar. 31 2023 -0.33 -0.46 Missed